All In Biotech

Drug Trial Radar · NCT05473624

Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

153

Planned (sponsor's estimate)

Start

Aug 23, 2022

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • HRS-1167Drug

    Participants will receive HRS-1167.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT) of HRS-1167Time frame: up to 24 days
  2. Maximum tolerated dose (MTD) of HRS-1167Time frame: up to 24 months
  3. Recommended Phase II Dose (RP2D) of HRS-1167Time frame: up to 24 months
  4. AEs+SAEsTime frame: up to 24 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Guangxi Medical University Affiliated Tumor Hosipital

    Nanning, Guangxi, China · Recruiting

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The First Affiliated Hospital with Nanjing Medical University

    Nanjing, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shangdong, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shangdong, China · Recruiting

  • Second Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China · Recruiting

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhengjiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.